Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 2, Pages e88865
Publisher
Public Library of Science (PLoS)
Online
2014-02-22
DOI
10.1371/journal.pone.0088865
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
- (2015) Tommy Alain et al. Oncotarget
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
- (2013) G S Ducker et al. ONCOGENE
- Pancreatic tumours escape from translational control through 4E-BP1 loss
- (2013) Y Martineau et al. ONCOGENE
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
- (2012) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
- (2012) M R Janes et al. LEUKEMIA
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting the translational machinery as a novel treatment strategy for hematologic malignancies
- (2010) P. R. Hagner et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Target of Rapamycin Signaling in Leukemia and Lymphoma
- (2010) C. Vu et al. CLINICAL CANCER RESEARCH
- The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
- (2010) P M Bhende et al. LEUKEMIA
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
- (2009) Nahum Sonenberg et al. CELL
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now